Feedback Regulatory News (FDBK)

Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement, this information is now considered to be in the public domain.

Feedback plc

Change of Nominated Adviser and Broker

London, 25 August 2021: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology and secure clinical communications company, is pleased to announce Panmure Gordon (UK) Limited has been appointed as the Company's Nominated Adviser and Sole Broker with immediate effect.

Dr Tom Oakley, CEO of Feedback, said: "In line with our strategy to drive clinical adoption of Bleepa both here in the UK and internationally, we are delighted to be working with Panmure Gordon, whose appointment, as industry specialists, signals a step change in our growth plans. We believe that their deep understanding of the sector, networks and broad institutional reach, will help us to progress our vision to enable clinicians to better securely communicate using everyday mobile technology, no matter their own location."

-Ends-

Enquiries:

Notes to Editors

Feedback plc (AIM: FDBK) is a medical imaging technology business with a secure clinical communications platform. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.

Its highly scalable Software as a Service ("SaaS") based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care providers. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of clinical review.